May 4th 2024
Durvalumab monotherapy as consolidation therapy in limited-stage small cell lung cancer produced a clinical benefit in patients from the phase 3 ADRIATIC trial.
Breaking Down Biomarkers in Non–Small Cell Lung Cancer: A Case-Based Discussion for the Oncology Nurse
View More
Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma
View More
Go To PER in Chicago
May 31, 2024 - June 2, 2024
Register Now!
The Top 10 Oncogenic Drivers in NSCLC for 2023: What You Need to Know on Tumor Testing, Targets, and Treatment Strategies to Move the Field Forward
View More
Expanding the Armamentarium of Actionable Mutations in NSCLC: Uncovering the Potential of CEACAM5 as a Therapeutic Target
View More
Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!
View More
Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer
View More
8th Annual School of Nursing Oncology™
August 10, 2024
Register Now!
Pathology Implications for CEACAM5 as a Therapeutic Target in Advanced NSCLC
View More
Medical Crossfire®: What Are Effective Strategies for Onco-Nurses to Improve Outcomes in Patients with Small Cell Lung Cancer?
View More
Virtual Show Me the Data™: How HER2, HER3, and TROP2 Targeted Strategies Will Impact Evolving Paradigms in NSCLC
View More
Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease
View More
42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care?
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
How CEACAM5 Expression Can Be Measured and Leveraged in NSCLC Care: Current Developments & Future Therapeutic Opportunities
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?
View More
22nd Annual Winter Lung Cancer Conference®
January 31, 2025 - February 2, 2025
Register Now!
Dialogues With the Surgeon on Integration of Systemic Therapies in Perioperative Settings for NSCLC: Looking at EGFR, ALK, IO, and Beyond…
View More
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care
View More
Can Online Searches Help Identify Pancreatic Cancer at an Earlier Stage?
September 1st 2016Researchers analyzed Bing.com search logs to identify those recently diagnosed with pancreatic cancer. Through symptom patterns expressed as searches, they were able to identify 5% to 15% of pancreatic cancer cases.
Lung Cancer Survival Improved in Patients Who Used a Web App to Report Symptoms
June 7th 2016Researchers in France have found that patients with lung cancer who used a web-based app to report and track their symptoms achieved impressive gains in survival compared with individuals who were followed using standard protocols.
Symptom Burden Higher in Newly Diagnosed Patients Reporting Financial Strain
March 25th 2016A study published by researchers at the Dana Farber-Cancer Institute recently discovered that financial status plays a large role in the level of symptom burden and quality of life for patients newly diagnosed with lung or colorectal cancer.
Changing the Face of Lung Cancer in Kentucky: New Program May Serve as National Model
December 23rd 2015Lung cancer remains the leading cause of cancer mortality, killing more Americans than breast, colon, and prostate cancer combined—and Kentucky is the epicenter of lung cancer in the United States.
For Patients With Lung Cancer, New Therapies Offer Reason to Hope
December 15th 2015FDA approval of two immunotherapies to treat non-small cell lung cancer (NSCLC), an ever-expanding understanding of the disease’s molecular differences, and new screening guidelines for high-risk patients to detect lung cancer at an earlier, more treatable stage, are helping patients live longer.